B. Riley lowered the firm’s price target on MediciNova (MNOV) to $5 from $6 and keeps a Buy rating on the shares. The firm points out the company’s current cash on hand of $37M implies a runway into 2027. It updated MediciNova’s model, now exclusively focused on amyotrophic lateral sclerosis-related risk-adjusted revenue and spending.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.